RxDoctor Payments Data

Sudha Thiruvengadam, MD

Internal Medicine · Derby, CTNPI 1639433832

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 74 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$307
  • Boehringer Ingelheim$121
  • MDD US Operations, LLC$109
  • Astellas Pharma US Inc$76
  • Sanofi-aventis U.S. LLC$62
  • AstraZeneca$59
  • plus $409 from 14 others

What the payments were for

  • Food & beverage$1,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,144 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$122,749
Medicare patients
178
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$127,048
JanuviaSitagliptin Phosphate50$55,594
OzempicSemaglutide24$43,243
EliquisApixaban22$24,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,523
Tresiba Flextouch U-100Insulin Degludec28$12,479
TradjentaLinagliptin11$12,240
Breo ElliptaFluticasone/Vilanterol16$6,224
Atorvastatin Calcium656$5,038
Novolog FlexpenInsulin Aspart17$2,333
Albuterol Sulfate HfaAlbuterol Sulfate103$2,292
Losartan Potassium251$2,167
Insulin Lispro Kwikpen U-100Insulin Lispro14$2,015
Levothyroxine Sodium236$1,872
SynthroidLevothyroxine Sodium27$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$121$139,28799 claims
MerckJanuvia$45$55,59450 claims
Novo NordiskOzempic$307$43,24324 claims
PfizerEliquis$19$24,95622 claims
GSKTrelegy Ellipta, Breo Ellipta$34$21,74730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →